Directing Tryptophan Immunometabolism to Ameliorate Liver Ischemic-Reperfusion Injury

指导色氨酸免疫代谢改善肝脏缺血再灌注损伤

基本信息

  • 批准号:
    10595020
  • 负责人:
  • 金额:
    $ 65.42万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-04-01 至 2025-12-31
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract Many different disease states and surgical interventions result in a period of inadequate tissue/organ blood supply (i.e., ischemia), that result in reperfusion injury when blood flow is restored, known as ischemia-reperfusion injury (IRI). IRI causes local inflammation, cell death, excessive tissue destruction and possible organ failure. Examples are found in transplantation, trauma, myocardial infarction, stroke, and in particular, IRI is a main cause of liver dysfunction and failure after liver surgery. Unfortunately, there are currently no therapies available in clinical practice addressing IRI, where a major problem is the harmful systemic side effects and toxicities of existing drugs. To address this problem, we are innovating a new therapeutic technology aiming to program immune cells toward a metabolic state blocking excessive inflammation by directing tryptophan metabolism through delivery of an enzyme into circulation. This represents a new class of anti- inflammatory/immunosuppressive biologic drug, with potential to limit systemic toxicities/side effects, and with potential to be significantly less immunocompromising. Lack of treatment options for liver IRI and a catalog of in vivo preliminary data strongly supporting the foundational rationale of IDO as an innovative new anti-inflammatory agent, make this proposal highly significant. Looking to the future, success would open opportunity to expand to other anti-inflammatory applications, for example, pre-conditioning donor grafts for transplantation.
项目总结/摘要 许多不同的疾病状态和手术干预导致一段时间的不充分 组织/器官血液供应(即,缺血),当血流被阻断时, 恢复,称为缺血再灌注损伤(IRI)。IRI导致局部炎症细胞死亡, 过度的组织破坏和可能的器官衰竭例如在移植中, 创伤、心肌梗塞、中风,特别是IRI是肝功能障碍的主要原因 以及肝脏手术后的衰竭不幸的是,目前临床上没有可用的治疗方法。 处理IRI的实践,其中一个主要问题是有害的全身副作用和毒性 现有的药物。 为了解决这个问题,我们正在创新一种新的治疗技术, 通过引导色氨酸,免疫细胞进入代谢状态, 通过将酶输送到循环中进行新陈代谢。这代表了一种新的反- 炎症/免疫抑制生物药物,可能限制全身毒性/副作用 效果,并且具有显著降低免疫妥协的潜力。缺乏治疗选择 对于肝脏IRI和一个强烈支持基本原理的体内初步数据目录 IDO作为一种创新的新型抗炎剂,使这一建议非常重要。 展望未来,成功将打开机会,扩大到其他抗炎药 例如,预处理供体移植物用于移植。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Benjamin George Keselowsky其他文献

Benjamin George Keselowsky的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Benjamin George Keselowsky', 18)}}的其他基金

Directing Tryptophan Immunometabolism to Ameliorate Liver Ischemic-Reperfusion Injury
指导色氨酸免疫代谢改善肝脏缺血再灌注损伤
  • 批准号:
    10444213
  • 财政年份:
    2022
  • 资助金额:
    $ 65.42万
  • 项目类别:
Diversity Supplement: Directing Tryptophan Immunometabolism to Ameliorate Liver Ischemic-Reperfusion Injury
多样性补充剂:引导色氨酸免疫代谢改善肝脏缺血再灌注损伤
  • 批准号:
    10632561
  • 财政年份:
    2022
  • 资助金额:
    $ 65.42万
  • 项目类别:
Functionalized Enzyme Treatments for Dual-Targeting of Inflammation in Spinal Cord Injury
功能化酶治疗脊髓损伤炎症的双重靶向
  • 批准号:
    10284992
  • 财政年份:
    2021
  • 资助金额:
    $ 65.42万
  • 项目类别:
Tissue-Targeted Enzyme for Localized Tryptophan Catabolism to Direct Subcutaneous and Oral Mucosal Inflammatory Responses
用于局部色氨酸分解代谢的组织靶向酶以指导皮下和口腔粘膜炎症反应
  • 批准号:
    9752509
  • 财政年份:
    2017
  • 资助金额:
    $ 65.42万
  • 项目类别:
Tissue-Targeted Enzyme for Localized Tryptophan Catabolism to Direct Subcutaneous and Oral Mucosal Inflammatory Responses
用于局部色氨酸分解代谢的组织靶向酶以指导皮下和口腔粘膜炎症反应
  • 批准号:
    9403768
  • 财政年份:
    2017
  • 资助金额:
    $ 65.42万
  • 项目类别:
Biomaterial Delivery System for Type 1 Diabetes Vaccine
1 型糖尿病疫苗的生物材料输送系统
  • 批准号:
    9285796
  • 财政年份:
    2014
  • 资助金额:
    $ 65.42万
  • 项目类别:
Biomaterial Delivery System for Type 1 Diabetes Vaccine
1 型糖尿病疫苗的生物材料输送系统
  • 批准号:
    8761784
  • 财政年份:
    2014
  • 资助金额:
    $ 65.42万
  • 项目类别:
Dendritic Cell-Targeting Microparticles for Subcellularly-Targeted Delivery of In
用于亚细胞靶向递送 In 的树突状细胞靶向微粒
  • 批准号:
    8707719
  • 财政年份:
    2012
  • 资助金额:
    $ 65.42万
  • 项目类别:
Dendritic Cell-Targeting Microparticles for Subcellularly-Targeted Delivery of In
用于亚细胞靶向递送 In 的树突状细胞靶向微粒
  • 批准号:
    9041572
  • 财政年份:
    2012
  • 资助金额:
    $ 65.42万
  • 项目类别:
Dendritic Cell-Targeting Microparticles for Subcellularly-Targeted Delivery of In
用于亚细胞靶向递送 In 的树突状细胞靶向微粒
  • 批准号:
    8821609
  • 财政年份:
    2012
  • 资助金额:
    $ 65.42万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 65.42万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.42万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 65.42万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.42万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 65.42万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 65.42万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.42万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 65.42万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 65.42万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.42万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了